RG 3039

Drug Profile

RG 3039

Alternative Names: PF 6687859; PF-06687859; Quinazoline 495; RG3039

Latest Information Update: 26 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Families of SMA
  • Developer Repligen Corporation
  • Class Small molecules
  • Mechanism of Action DcpS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Spinal muscular atrophy

Most Recent Events

  • 06 Nov 2014 Phase-I development is ongoing in USA
  • 03 Jan 2013 RG 3039 sub-licensed to Pfizer worldwide
  • 26 Sep 2012 Repligen initiates enrolment in a phase Ib trial in healthy volunteers in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top